Stock ITCI INTRA-CELLULAR THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
73.12 USD -1.20% Intraday chart for Intra-Cellular Therapies, Inc. -4.66% +2.09%
Apr. 23 Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating MT
Apr. 22 Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating MT

Evolution of the average Target Price on Intra-Cellular Therapies, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9.oBYgi9JDLS9eBQ72wcaY_xcBneN8ct_or7Au9a5F-Ls.ziBD-pAxRhxufTu-jpLfhV9w-rofSoCt2ONJgs09q-rFZlO7lRRHGDB8Rw~a0fa6b10d66fe428f07cdf717500b95b

Analyst Recommendations on Intra-Cellular Therapies, Inc.

Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating MT
Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating MT
Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating MT
Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating MT
BofA Securities Adjusts Price Target on Intra-Cellular Therapies to $91 From $82, Maintains Buy Rating MT
Baird Adjusts Price Target on Intra-Cellular Therapies to $103 From $83, Maintains Outperform Rating MT
TD Cowen Adjusts Price Target on Intra-Cellular Therapies to $90 From $80, Maintains Buy Rating MT
Morgan Stanley Lifts Price Target on Intra-Cellular Therapies to $92 From $85, Says Study 501 Exceeds Its Highest Expectations; Overweight Kept MT
Needham Adjusts Intra-Cellular Therapies Price Target to $82 From $72, Maintains Buy Rating MT
Mizuho Increases PT on Intra-Cellular Therapies to $82 From $76 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating MT
Goldman Sachs Raises Intra-Cellular Therapies' Price Target to $64 From $58, Keeps Neutral Rating MT
Baird Initiates Intra-Cellular Therapies With Outperform Rating, Price Target is $83 MT
RBC Boosts Price Target on Intra-Cellular Therapies to $86 From $76, Keeps Outperform Rating MT
TD Cowen Starts Coverage on Intra-Cellular Therapies with Outperform Rating, $75 Price Target MT
RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating MT
Needham Adjusts Price Target on Intra-Cellular Therapies to $72 From $73, Maintains Buy Rating MT
RBC Lifts Price Target on Intra-Cellular Therapies to $79 From $78, Keeps Outperform Rating MT
RBC Raises Intra-Cellular Therapies' Price Target to $78 From $76, Keeps Outperform Rating MT
Needham Adjusts Intra-Cellular Therapies' Price Target to $73 From $70, Keeps Buy Rating MT
UBS Adjusts Intra-Cellular Therapies Price Target to $80 From $74, Maintains Buy Rating MT
JPMorgan Adjusts Price Target on Intra-Cellular Therapies to $62 From $58, Maintains Overweight Rating MT
Mizuho Securities Adjusts Intra-Cellular Therapies Price Target to $76 From $74, Maintains Buy Rating MT
RBC Boosts Price Target on Intra-Cellular Therapies to $76 From $72, Maintains Outperform Rating MT
Morgan Stanley Initiates Intra-Cellular Therapies at Overweight With $80 Price Target MT
RBC Capital Adjusts Intra-Cellular Therapies Price Target to $72 From $71, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
73.12 USD
Average target price
90.28 USD
Spread / Average Target
+23.47%
High Price Target
120 USD
Spread / Highest target
+64.11%
Low Price Target
65 USD
Spread / Lowest Target
-11.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Intra-Cellular Therapies, Inc.

Canaccord Genuity
Needham & Co.
Mizuho Securities
Goldman Sachs
Baird
BofA Securities
TD Cowen
Morgan Stanley
RBC Capital Markets
UBS
JPMorgan Chase
Piper Sandler
SVB Leerink
Jefferies & Co.

Ratings for Intra-Cellular Therapies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ITCI Stock
  4. Consensus Intra-Cellular Therapies, Inc.